DeliverEX

WIPO WIPO 2020

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke DeliverEX wurde als Wortmarke am 31.01.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 17. November 2021

Markenform Wortmarke
Aktenzeichen 1524524
Länder Japan Vereinigte Staaten von Amerika (USA)
Basismarke EU Nr. 018146694, 05. November 2019
Anmeldedatum 31. Januar 2020
Ablaufdatum 31. Januar 2030

Markeninhaber

Oxford Science Park,
Medawar Centre, 2nd Floor
GB

Markenvertreter

80 Turnmill Street London EC1M 5QU GB

Waren und Dienstleistungen

05 Pharmaceuticals; pharmaceutical preparations and substances; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; medicine; medical preparations and articles; biological preparations for medical purposes; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosome; biological preparations comprising a therapeutic target protein-loaded exosome; biological preparations comprising exosome for pharmaceutical purposes; biological reagents for medical use; mixed biological preparations for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutics for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy
42 Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services; biological research; clinical research; providing medical and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science
44 Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; laboratory analysis service relating to the diagnosis and treatment of persons; medical analysis and examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
01. November 2021 2021/44 Gaz US RAW: Rule 18ter(2)(ii) GP following a provisional refusal
20. Mai 2021 2021/21 Gaz JP Ablehnung
03. März 2021 2021/15 Gaz EM RAW: Partial Ceasing Effect
14. Mai 2020 2020/20 Gaz US Ablehnung
31. Januar 2020 2020/13 Gaz EM Eintragung

ID: 141524524